Cardiovascular outcomes, long-term efficacy and safety In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109]
Ortuno Macias LE, Jimenez-Angeles F, Marmorstein JG, Wang Y, Crane SA, K TS, Sun P, Sapkota B, Hummingbird E, Jung W, Qiao B, Lee D, Dmochowski IJ, Messinger RJ, Schlossman ML, de la Fuente-Nunez C, Radhakrishnan R, Petersson EJ, Olvera de la Cruz M, Bu W, Bera M, Lin B, Tu RS, Stebe KJ, Maldarelli C (2024) Lanthanide binding peptide surfactants at air-aqueous interfaces for interfacial separation of rare earth elements
10.1016/j.neuint.2021.105221 Neurochem
SC is often selected when patients self-inject frequently, when comfort is a priority, or when body composition makes IM targeting difficult
The primary cause of the renal disease is the absence of a clinical manifestation in the early stages and the fact that routinely evaluated indicators of renal function are only significantly diminished during the advanced stages of the disease (Tonelli and Dickinson 2020)
